Is TECX or SPRB more profitable?

Tectonic Therapeutic's return on equity of -32.33% beat Spruce Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Tectonic Therapeutic N/A -32.33% -30.92% Spruce Biosciences N/A -155.40% -101.67%

Does the media prefer TECX or SPRB?

In the previous week, Spruce Biosciences had 1 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 2 mentions for Spruce Biosciences and 1 mentions for Tectonic Therapeutic. Spruce Biosciences' average media sentiment score of 0.50 beat Tectonic Therapeutic's score of 0.00 indicating that Spruce Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tectonic Therapeutic 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Spruce Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to SPRB or DNA?

In the previous week, Spruce Biosciences had 1 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 2 mentions for Spruce Biosciences and 1 mentions for Ginkgo Bioworks. Spruce Biosciences' average media sentiment score of 0.50 beat Ginkgo Bioworks' score of 0.00 indicating that Spruce Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spruce Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ginkgo Bioworks 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to SPRB or ZSQR?

In the previous week, Spruce Biosciences had 1 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 2 mentions for Spruce Biosciences and 1 mentions for Coeptis Therapeutics. Spruce Biosciences' average media sentiment score of 0.50 beat Coeptis Therapeutics' score of 0.00 indicating that Spruce Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spruce Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Coeptis Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is CABA or SPRB more profitable?

Cabaletta Bio's return on equity of -131.58% beat Spruce Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Cabaletta Bio N/A -131.58% -96.46% Spruce Biosciences N/A -155.40% -101.67%

Does the media prefer CABA or SPRB?

In the previous week, Cabaletta Bio and Cabaletta Bio both had 2 articles in the media. Spruce Biosciences' average media sentiment score of 0.50 beat Cabaletta Bio's score of 0.25 indicating that Spruce Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cabaletta Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Spruce Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PRME or SPRB?

In the previous week, Prime Medicine had 3 more articles in the media than Spruce Biosciences. MarketBeat recorded 5 mentions for Prime Medicine and 2 mentions for Spruce Biosciences. Spruce Biosciences' average media sentiment score of 0.50 beat Prime Medicine's score of 0.35 indicating that Spruce Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prime Medicine 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Spruce Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Spruce Biosciences (SPRB) Competitors

$52.36 +3.60 (+7.38%)

Closing price 04:00 PM Eastern

Extended Trading

$50.24 -2.12 (-4.04%)

As of 06:08 PM Eastern

Compare

SPRB vs. TECX, DNA, ZSQR, CABA, and PRME

Should you buy Spruce Biosciences stock or one of its competitors? MarketBeat compares Spruce Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Spruce Biosciences include Tectonic Therapeutic (TECX), Ginkgo Bioworks (DNA), Coeptis Therapeutics (ZSQR), Cabaletta Bio (CABA), and Prime Medicine (PRME). These companies are all part of the "pharmaceutical products" industry.

How does Spruce Biosciences compare to Tectonic Therapeutic?

Tectonic Therapeutic (NASDAQ:TECX) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings, media sentiment and risk.

Spruce Biosciences has higher revenue and earnings than Tectonic Therapeutic. Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.46	N/A
Spruce Biosciences	$4.91M	29.33	-$38.97M	-$36.60	N/A

62.6% of Tectonic Therapeutic shares are owned by institutional investors. Comparatively, 91.7% of Spruce Biosciences shares are owned by institutional investors. 39.8% of Tectonic Therapeutic shares are owned by company insiders. Comparatively, 4.3% of Spruce Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Tectonic Therapeutic's return on equity of -32.33% beat Spruce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tectonic Therapeutic	N/A	-32.33%	-30.92%
Spruce Biosciences	N/A	-155.40%	-101.67%

In the previous week, Spruce Biosciences had 1 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 2 mentions for Spruce Biosciences and 1 mentions for Tectonic Therapeutic. Spruce Biosciences' average media sentiment score of 0.50 beat Tectonic Therapeutic's score of 0.00 indicating that Spruce Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tectonic Therapeutic	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Spruce Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tectonic Therapeutic has a beta of 3.19, suggesting that its stock price is 219% more volatile than the broader market. Comparatively, Spruce Biosciences has a beta of 3.11, suggesting that its stock price is 211% more volatile than the broader market.

Tectonic Therapeutic presently has a consensus target price of $79.40, suggesting a potential upside of 164.49%. Spruce Biosciences has a consensus target price of $163.00, suggesting a potential upside of 211.31%. Given Spruce Biosciences' higher possible upside, analysts plainly believe Spruce Biosciences is more favorable than Tectonic Therapeutic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tectonic Therapeutic	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
Spruce Biosciences	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

Spruce Biosciences beats Tectonic Therapeutic on 8 of the 15 factors compared between the two stocks.

How does Spruce Biosciences compare to Ginkgo Bioworks?

Spruce Biosciences (NASDAQ:SPRB) and Ginkgo Bioworks (NYSE:DNA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, dividends, valuation, risk, profitability, earnings and analyst recommendations.

Spruce Biosciences presently has a consensus price target of $163.00, suggesting a potential upside of 211.31%. Ginkgo Bioworks has a consensus price target of $8.50, suggesting a potential downside of 7.38%. Given Spruce Biosciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Spruce Biosciences is more favorable than Ginkgo Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spruce Biosciences	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
Ginkgo Bioworks	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

Spruce Biosciences has a net margin of 0.00% compared to Ginkgo Bioworks' net margin of -215.41%. Ginkgo Bioworks' return on equity of -56.08% beat Spruce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spruce Biosciences	N/A	-155.40%	-101.67%
Ginkgo Bioworks	-215.41%	-56.08%	-26.06%

In the previous week, Spruce Biosciences had 1 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 2 mentions for Spruce Biosciences and 1 mentions for Ginkgo Bioworks. Spruce Biosciences' average media sentiment score of 0.50 beat Ginkgo Bioworks' score of 0.00 indicating that Spruce Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spruce Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ginkgo Bioworks	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Spruce Biosciences has higher earnings, but lower revenue than Ginkgo Bioworks. Ginkgo Bioworks is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spruce Biosciences	$4.91M	29.33	-$38.97M	-$36.60	N/A
Ginkgo Bioworks	$170.15M	3.52	-$312.76M	-$5.36	N/A

91.7% of Spruce Biosciences shares are owned by institutional investors. Comparatively, 78.6% of Ginkgo Bioworks shares are owned by institutional investors. 4.3% of Spruce Biosciences shares are owned by company insiders. Comparatively, 12.7% of Ginkgo Bioworks shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Spruce Biosciences has a beta of 3.11, meaning that its stock price is 211% more volatile than the broader market. Comparatively, Ginkgo Bioworks has a beta of 1.79, meaning that its stock price is 79% more volatile than the broader market.

Summary

Spruce Biosciences beats Ginkgo Bioworks on 11 of the 16 factors compared between the two stocks.

How does Spruce Biosciences compare to Coeptis Therapeutics?

Spruce Biosciences (NASDAQ:SPRB) and Coeptis Therapeutics (NASDAQ:ZSQR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.

Spruce Biosciences has a beta of 3.11, indicating that its share price is 211% more volatile than the broader market. Comparatively, Coeptis Therapeutics has a beta of -0.22, indicating that its share price is 122% less volatile than the broader market.

Spruce Biosciences presently has a consensus price target of $163.00, indicating a potential upside of 211.31%. Given Spruce Biosciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Spruce Biosciences is more favorable than Coeptis Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spruce Biosciences	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
Coeptis Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Coeptis Therapeutics has lower revenue, but higher earnings than Spruce Biosciences. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spruce Biosciences	$4.91M	29.33	-$38.97M	-$36.60	N/A
Coeptis Therapeutics	$1.36M	632.66	-$11.92M	-$2.52	N/A

91.7% of Spruce Biosciences shares are owned by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are owned by institutional investors. 4.3% of Spruce Biosciences shares are owned by company insiders. Comparatively, 24.3% of Coeptis Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Spruce Biosciences had 1 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 2 mentions for Spruce Biosciences and 1 mentions for Coeptis Therapeutics. Spruce Biosciences' average media sentiment score of 0.50 beat Coeptis Therapeutics' score of 0.00 indicating that Spruce Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spruce Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Coeptis Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Spruce Biosciences has a net margin of 0.00% compared to Coeptis Therapeutics' net margin of -810.04%. Coeptis Therapeutics' return on equity of -92.29% beat Spruce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spruce Biosciences	N/A	-155.40%	-101.67%
Coeptis Therapeutics	-810.04%	-92.29%	-73.52%

Summary

Spruce Biosciences beats Coeptis Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Spruce Biosciences compare to Cabaletta Bio?

Cabaletta Bio (NASDAQ:CABA) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, media sentiment, institutional ownership and valuation.

In the previous week, Cabaletta Bio and Cabaletta Bio both had 2 articles in the media. Spruce Biosciences' average media sentiment score of 0.50 beat Cabaletta Bio's score of 0.25 indicating that Spruce Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cabaletta Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Spruce Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cabaletta Bio's return on equity of -131.58% beat Spruce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cabaletta Bio	N/A	-131.58%	-96.46%
Spruce Biosciences	N/A	-155.40%	-101.67%

Spruce Biosciences has higher revenue and earnings than Cabaletta Bio. Cabaletta Bio is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.96	N/A
Spruce Biosciences	$4.91M	29.33	-$38.97M	-$36.60	N/A

Cabaletta Bio has a beta of 3.21, suggesting that its stock price is 221% more volatile than the broader market. Comparatively, Spruce Biosciences has a beta of 3.11, suggesting that its stock price is 211% more volatile than the broader market.

Cabaletta Bio currently has a consensus target price of $15.50, indicating a potential upside of 445.77%. Spruce Biosciences has a consensus target price of $163.00, indicating a potential upside of 211.31%. Given Cabaletta Bio's higher possible upside, equities research analysts plainly believe Cabaletta Bio is more favorable than Spruce Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Spruce Biosciences	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

91.7% of Spruce Biosciences shares are held by institutional investors. 6.4% of Cabaletta Bio shares are held by company insiders. Comparatively, 4.3% of Spruce Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Spruce Biosciences beats Cabaletta Bio on 7 of the 13 factors compared between the two stocks.

How does Spruce Biosciences compare to Prime Medicine?

Prime Medicine (NASDAQ:PRME) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

Spruce Biosciences has a net margin of 0.00% compared to Prime Medicine's net margin of -4,917.55%. Spruce Biosciences' return on equity of -155.40% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prime Medicine	-4,917.55%	-188.82%	-60.97%
Spruce Biosciences	N/A	-155.40%	-101.67%

70.4% of Prime Medicine shares are held by institutional investors. Comparatively, 91.7% of Spruce Biosciences shares are held by institutional investors. 16.0% of Prime Medicine shares are held by company insiders. Comparatively, 4.3% of Spruce Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Spruce Biosciences has higher revenue and earnings than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prime Medicine	$4.63M	126.00	-$201.14M	-$1.23	N/A
Spruce Biosciences	$4.91M	29.33	-$38.97M	-$36.60	N/A

Prime Medicine has a beta of 2.31, indicating that its stock price is 131% more volatile than the broader market. Comparatively, Spruce Biosciences has a beta of 3.11, indicating that its stock price is 211% more volatile than the broader market.

Prime Medicine currently has a consensus target price of $7.65, suggesting a potential upside of 136.84%. Spruce Biosciences has a consensus target price of $163.00, suggesting a potential upside of 211.31%. Given Spruce Biosciences' higher possible upside, analysts clearly believe Spruce Biosciences is more favorable than Prime Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prime Medicine	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Spruce Biosciences	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, Prime Medicine had 3 more articles in the media than Spruce Biosciences. MarketBeat recorded 5 mentions for Prime Medicine and 2 mentions for Spruce Biosciences. Spruce Biosciences' average media sentiment score of 0.50 beat Prime Medicine's score of 0.35 indicating that Spruce Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prime Medicine	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Spruce Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Spruce Biosciences beats Prime Medicine on 10 of the 17 factors compared between the two stocks.

Get Spruce Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SPRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SPRB vs. The Competition

Export

Metric	Spruce Biosciences	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$134.20M	$933.75M	$6.66B	$12.38B
Dividend Yield	N/A	4.84%	2.68%	5.68%
P/E Ratio	-1.43	1.41	24.48	24.42
Price / Sales	29.33	123.34	577.04	128.85
Price / Cash	N/A	20.06	44.20	55.24
Price / Book	1.32	7.76	10.70	6.58
Net Income	-$38.97M	-$5.03M	$3.57B	$337.29M
7 Day Performance	6.64%	1.42%	0.56%	0.55%
1 Month Performance	1.85%	3.97%	3.57%	4.43%
1 Year Performance	870.98%	49.79%	28.49%	31.16%

Spruce Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SPRB Spruce Biosciences	2.5949 of 5 stars	$52.36 +7.4%	$163.00 +211.3%	+794.3%	$134.20M	$4.91M	N/A	20	Analyst Forecast High Trading Volume
TECX Tectonic Therapeutic	2.4474 of 5 stars	$28.56 -1.9%	$79.40 +178.0%	+46.6%	$538.93M	N/A	N/A	120	News Coverage
DNA Ginkgo Bioworks	0.1527 of 5 stars	$8.25 +1.9%	$8.50 +3.1%	-0.8%	$538.56M	$170.15M	N/A	640
ZSQR Coeptis Therapeutics	0.1073 of 5 stars	$10.33 +2.5%	N/A	+89.9%	$531.27M	$1.36M	N/A	2	High Trading Volume
CABA Cabaletta Bio	2.7266 of 5 stars	$3.22 +0.6%	$15.50 +381.4%	+52.3%	$525.02M	N/A	N/A	50

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SPRB) was last updated on 6/18/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Spruce Biosciences (SPRB) Competitors

SPRB vs. TECX, DNA, ZSQR, CABA, and PRME

How does Spruce Biosciences compare to Tectonic Therapeutic?

Summary

How does Spruce Biosciences compare to Ginkgo Bioworks?

Summary

How does Spruce Biosciences compare to Coeptis Therapeutics?

Summary

How does Spruce Biosciences compare to Cabaletta Bio?

Summary

How does Spruce Biosciences compare to Prime Medicine?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRB vs. The Competition

Spruce Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Spruce Biosciences (SPRB) Competitors

SPRB vs. TECX, DNA, ZSQR, CABA, and PRME

How does Spruce Biosciences compare to Tectonic Therapeutic?

Which has preferable valuation & earnings, TECX or SPRB?

Do institutionals & insiders have more ownership in TECX or SPRB?

Is TECX or SPRB more profitable?

Does the media prefer TECX or SPRB?

Which has more risk & volatility, TECX or SPRB?

Do analysts rate TECX or SPRB?

Summary

How does Spruce Biosciences compare to Ginkgo Bioworks?

Do analysts rate SPRB or DNA?

Is SPRB or DNA more profitable?

Does the media refer more to SPRB or DNA?

Which has higher valuation and earnings, SPRB or DNA?

Do insiders & institutionals hold more shares of SPRB or DNA?

Which has more volatility & risk, SPRB or DNA?

Summary

How does Spruce Biosciences compare to Coeptis Therapeutics?

Which has more volatility & risk, SPRB or ZSQR?

Do analysts prefer SPRB or ZSQR?

Which has preferable earnings & valuation, SPRB or ZSQR?

Do institutionals & insiders believe in SPRB or ZSQR?

Does the media refer more to SPRB or ZSQR?

Is SPRB or ZSQR more profitable?

Summary

How does Spruce Biosciences compare to Cabaletta Bio?

Does the media prefer CABA or SPRB?

Is CABA or SPRB more profitable?

Which has stronger earnings and valuation, CABA or SPRB?

Which has more risk & volatility, CABA or SPRB?

Do analysts rate CABA or SPRB?

Do institutionals & insiders believe in CABA or SPRB?

Summary

How does Spruce Biosciences compare to Prime Medicine?

Is PRME or SPRB more profitable?

Do institutionals and insiders hold more shares of PRME or SPRB?

Which has preferable earnings & valuation, PRME or SPRB?

Which has more risk & volatility, PRME or SPRB?

Do analysts recommend PRME or SPRB?

Does the media favor PRME or SPRB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRB vs. The Competition

Spruce Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools